INDIANAPOLIS, Dec. 9, 2016 /PRNewswire/ — Eli Lilly and Company (NYSE:LLY) today presented detailed results of its phase 3 EXPEDITION3 trial at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) meeting. As previously disclosed, solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a study of solanezumab initiated in people with mild dementia […]